ESTRO 2024 - Abstract Book

S873

Clinical - CNS

ESTRO 2024

After surgery and FSRT, some grade of loss of independence in activities of daily living was observed in 13p and 1p, respectively and improvement occurred in 2p and 3p respectively.

Median follow-up was 115 months (range 15-226). Five and 10-year actuarial overall survival (OS) and relapse-free survival (RFS) were 97% and 81%; and 96% and 86% respectively. Enlargement cystic component during follow-up was observed in 7p (22.6%) and 3p required drainage. Two patients died due to tumour progression.

Tumour volume prior surgery in MRI was higher in deceased patients (17.4cc vs 5.8cc; p=0.001) and in relapsed patients (24cc vs 6.3cc; p<0.001).

Planning target volume was higher in relapsed patients (19.1cc vs 7.6cc; p=0.016).

Five-year OS and RFS was better in patients with stable and partial MRI response compared to those with progression (96% and 100% vs 66%, p=0.025 (Figure 1); and 100% and 100% vs 66%, p<0.001,respectively)

Conclusion:

In our series, FSRT is effective and well-tolerated, providing improvement in some cases. Long-term outcomes are good in terms of local control and treatment-related complications. Further studies are needed to determine whether a less aggressive surgery in combination with postoperative FSRT can achieve same tumour control while reducing complications.

Keywords: craniopharyngioma,radiotherapy

References:

Elliott RE, Sands SA, Strom RG, Wisoff JH. Craniopharyngioma Clinical Status Scale: a standardized metric of preoperative function and posttreatment outcome. Neurosurg Focus. 2010 Apr;28(4):E2. doi:10.3171/2010.2.FOCUS09304. PMID: 20367359.